Skip to main content
Top
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Research

Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes

Authors: Yurie Motohashi, Manabu Igarashi, Masatoshi Okamatsu, Takeshi Noshi, Yoshihiro Sakoda, Naoki Yamamoto, Kimihito Ito, Ryu Yoshida, Hiroshi Kida

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

The hemagglutinin (HA) of influenza viruses is a possible target for antiviral drugs because of its key roles in the initiation of infection. Although it was found that a natural compound, Stachyflin, inhibited the growth of H1 and H2 but not H3 influenza viruses in MDCK cells, inhibitory activity of the compound has not been assessed against H4-H16 influenza viruses and the precise mechanism of inhibition has not been clarified.

Methods

Inhibitory activity of Stachyflin against H4-H16 influenza viruses, as well as H1-H3 viruses was examined in MDCK cells. To identify factors responsible for the susceptibility of the viruses to this compound, Stachyflin-resistant viruses were selected in MDCK cells and used for computer docking simulation.

Results

It was found that in addition to antiviral activity of Stachyflin against influenza viruses of H1 and H2 subtypes, it inhibited replication of viruses of H5 and H6 subtypes, as well as A(H1N1)pdm09 virus in MDCK cells. Stachyflin also inhibited the virus growth in the lungs of mice infected with A/WSN/1933 (H1N1) and A/chicken/Ibaraki/1/2005 (H5N2). Substitution of amino acid residues was found on the HA2 subunit of Stachyflin-resistant viruses. Docking simulation indicated that D37, K51, T107, and K121 are responsible for construction of the cavity for the binding of the compound. In addition, 3-dimensional structure of the cavity of the HA of Stachyflin-susceptible virus strains was different from that of insusceptible virus strains.

Conclusion

Antiviral activity of Stachyflin was found against A(H1N1)pdm09, H5, and H6 viruses, and identified a potential binding pocket for Stachyflin on the HA. The present results should provide us with useful information for the development of HA inhibitors with more effective and broader spectrum.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of Amantadine. EMBO J 1985, 4: 3021-3024.PubMedPubMedCentral Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of Amantadine. EMBO J 1985, 4: 3021-3024.PubMedPubMedCentral
2.
go back to reference Moscona A: Medical management of influenza infection. Annu Rev Med 2008, 59: 397-413. 10.1146/annurev.med.59.061506.213121PubMedCrossRef Moscona A: Medical management of influenza infection. Annu Rev Med 2008, 59: 397-413. 10.1146/annurev.med.59.061506.213121PubMedCrossRef
3.
go back to reference Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell 1992, 69: 517-528. 10.1016/0092-8674(92)90452-IPubMedCrossRef Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell 1992, 69: 517-528. 10.1016/0092-8674(92)90452-IPubMedCrossRef
4.
go back to reference Palese P, Tobita K, Ueda M, Compans RW: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61: 397-410. 10.1016/0042-6822(74)90276-1PubMedCrossRef Palese P, Tobita K, Ueda M, Compans RW: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61: 397-410. 10.1016/0042-6822(74)90276-1PubMedCrossRef
5.
go back to reference Gubareva LV, Kaiser L, Hayden FG: Influenza virus neuraminidase inhibitors. Lancet 2000, 355: 827-835. 10.1016/S0140-6736(99)11433-8PubMedCrossRef Gubareva LV, Kaiser L, Hayden FG: Influenza virus neuraminidase inhibitors. Lancet 2000, 355: 827-835. 10.1016/S0140-6736(99)11433-8PubMedCrossRef
6.
go back to reference Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Frederick GH, Sugaya N, Kawaoka Y: Resistant influenza a viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364: 759-765. 10.1016/S0140-6736(04)16934-1PubMedCrossRef Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Frederick GH, Sugaya N, Kawaoka Y: Resistant influenza a viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364: 759-765. 10.1016/S0140-6736(04)16934-1PubMedCrossRef
7.
go back to reference Shental-Bechor D, Danieli T, Henis Y, Ben-Tal N: Long-range effects on the binding of the influenza HA to receptors are mediated by changes in the stability of a metastable HA conformation. Biochim Biophys Acta 2002, 1565: 81-89. 10.1016/S0005-2736(02)00511-4PubMedCrossRef Shental-Bechor D, Danieli T, Henis Y, Ben-Tal N: Long-range effects on the binding of the influenza HA to receptors are mediated by changes in the stability of a metastable HA conformation. Biochim Biophys Acta 2002, 1565: 81-89. 10.1016/S0005-2736(02)00511-4PubMedCrossRef
8.
go back to reference Feng F, Miura N, Isoda N, Sakoda Y, Okamatsu M, Kida H, Nishimura S: Novel trivalent anti-influenza reagent. Bioorg Med Chem Lett 2010, 20: 3772-3776. 10.1016/j.bmcl.2010.04.060PubMedCrossRef Feng F, Miura N, Isoda N, Sakoda Y, Okamatsu M, Kida H, Nishimura S: Novel trivalent anti-influenza reagent. Bioorg Med Chem Lett 2010, 20: 3772-3776. 10.1016/j.bmcl.2010.04.060PubMedCrossRef
9.
go back to reference O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003, 47: 2518-2525. 10.1128/AAC.47.8.2518-2525.2003PubMedPubMedCentralCrossRef O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003, 47: 2518-2525. 10.1128/AAC.47.8.2518-2525.2003PubMedPubMedCentralCrossRef
10.
go back to reference Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza a virus. J Virol 1997, 71: 4062-4070.PubMedPubMedCentral Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza a virus. J Virol 1997, 71: 4062-4070.PubMedPubMedCentral
11.
go back to reference Vanderlinden E, Göktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L: Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 2010, 84: 4277-4288. 10.1128/JVI.02325-09PubMedPubMedCentralCrossRef Vanderlinden E, Göktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L: Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 2010, 84: 4277-4288. 10.1128/JVI.02325-09PubMedPubMedCentralCrossRef
12.
go back to reference Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y: Inhibition of influenza a virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999, 73: 140-151.PubMedPubMedCentral Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y: Inhibition of influenza a virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999, 73: 140-151.PubMedPubMedCentral
13.
go back to reference Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N: Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol 1999, 144: 865-878. 10.1007/s007050050552PubMedCrossRef Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N: Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol 1999, 144: 865-878. 10.1007/s007050050552PubMedCrossRef
14.
go back to reference Yoshimoto J, Kakui M, Iwasaki H, Sugimoto H, Fujiwara T, Hattori N: Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, stachyflin. Microbiol Immunol 2000, 44: 677-685.PubMedCrossRef Yoshimoto J, Kakui M, Iwasaki H, Sugimoto H, Fujiwara T, Hattori N: Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, stachyflin. Microbiol Immunol 2000, 44: 677-685.PubMedCrossRef
15.
go back to reference Yagi S, Ono J, Yoshimoto J, Sugita K, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hirano K, Hashimoto N: Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of stachyflin and its derivatives. Pharm Res 1999, 16: 1041-1046. 10.1023/A:1018983715982PubMedCrossRef Yagi S, Ono J, Yoshimoto J, Sugita K, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hirano K, Hashimoto N: Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of stachyflin and its derivatives. Pharm Res 1999, 16: 1041-1046. 10.1023/A:1018983715982PubMedCrossRef
16.
go back to reference Yoshimoto J, Yagi S, Ono J, Sugita K, Hattori N, Fujita T, Fujiwara T, Sugimoto H, Hashimoto N: Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. J Pharm Pharmacol 2000, 52: 1247-1255. 10.1211/0022357001777225PubMedCrossRef Yoshimoto J, Yagi S, Ono J, Sugita K, Hattori N, Fujita T, Fujiwara T, Sugimoto H, Hashimoto N: Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. J Pharm Pharmacol 2000, 52: 1247-1255. 10.1211/0022357001777225PubMedCrossRef
17.
go back to reference Kida H, Webster RG, Yanagawa R: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of a/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983, 76: 91-99. 10.1007/BF01311693PubMedCrossRef Kida H, Webster RG, Yanagawa R: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of a/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983, 76: 91-99. 10.1007/BF01311693PubMedCrossRef
18.
go back to reference Yanagita H, Yamamoto N, Fuji H, Liu X, Ogata M, Yokota M, Takaku H, Hasegawa H, Odagiri T, Tashiro M, Hoshino T: Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. ACS Chem Biol 2012, 7: 552-562. 10.1021/cb200332kPubMedCrossRef Yanagita H, Yamamoto N, Fuji H, Liu X, Ogata M, Yokota M, Takaku H, Hasegawa H, Odagiri T, Tashiro M, Hoshino T: Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. ACS Chem Biol 2012, 7: 552-562. 10.1021/cb200332kPubMedCrossRef
19.
go back to reference Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ: Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008, 105: 17736-17741. 10.1073/pnas.0807142105PubMedPubMedCentralCrossRef Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ: Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008, 105: 17736-17741. 10.1073/pnas.0807142105PubMedPubMedCentralCrossRef
20.
go back to reference Liu S, Li R, Zhang R, Chan CC, Xi B, Zhu Z, Yang J, Poon VK, Zhou J, Chen M: CL-385319 inhibits H5N1 avian influenza a virus infection by blocking viral entry. Eur J Pharmacol 2011, 660: 460-467. 10.1016/j.ejphar.2011.04.013PubMedCrossRef Liu S, Li R, Zhang R, Chan CC, Xi B, Zhu Z, Yang J, Poon VK, Zhou J, Chen M: CL-385319 inhibits H5N1 avian influenza a virus infection by blocking viral entry. Eur J Pharmacol 2011, 660: 460-467. 10.1016/j.ejphar.2011.04.013PubMedCrossRef
21.
go back to reference Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG: Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009, 53: 3088-3096. 10.1128/AAC.01667-08PubMedPubMedCentralCrossRef Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG: Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009, 53: 3088-3096. 10.1128/AAC.01667-08PubMedPubMedCentralCrossRef
22.
go back to reference Rachakonda PS, Veit M, Korte T, Ludwig K, Böttcher C, Huang Q, Schmidt MF, Herrmann A: The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J 2007, 21: 995-1002. 10.1096/fj.06-7052hypPubMedCrossRef Rachakonda PS, Veit M, Korte T, Ludwig K, Böttcher C, Huang Q, Schmidt MF, Herrmann A: The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J 2007, 21: 995-1002. 10.1096/fj.06-7052hypPubMedCrossRef
23.
go back to reference Mueller DS, Kampmann T, Yennamalli R, Young PR, Kobe B, Mark AE: Histidine protonation and the activation of viral fusion proteins. Biochem Soc Trans 2008, 36: 43-45. 10.1042/BST0360043PubMedCrossRef Mueller DS, Kampmann T, Yennamalli R, Young PR, Kobe B, Mark AE: Histidine protonation and the activation of viral fusion proteins. Biochem Soc Trans 2008, 36: 43-45. 10.1042/BST0360043PubMedCrossRef
25.
go back to reference Minagawa K, Kouzuki S, Tani H, Ishii K, Tanimoto T, Terui Y, Kamigauchi T: Novel stachyflin derivatives from stachybotrys sp. RF-7260. Fermentation, isolation, structure elucidation and biological activities. J Antibiot (Tokyo) 2002, 55: 239-248. 10.7164/antibiotics.55.239CrossRef Minagawa K, Kouzuki S, Tani H, Ishii K, Tanimoto T, Terui Y, Kamigauchi T: Novel stachyflin derivatives from stachybotrys sp. RF-7260. Fermentation, isolation, structure elucidation and biological activities. J Antibiot (Tokyo) 2002, 55: 239-248. 10.7164/antibiotics.55.239CrossRef
26.
go back to reference Tobita K: Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol 1975, 162: 23-27. 10.1007/BF02123574PubMedCrossRef Tobita K: Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol 1975, 162: 23-27. 10.1007/BF02123574PubMedCrossRef
27.
go back to reference Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27: 493-497. Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27: 493-497.
28.
go back to reference Skehel JJ, Hay AJ: Nucleotide sequences at the 5’ termini of influenza virus RNAs and their transcripts. Nucleic Acids Res 1978, 5: 1207-1219. 10.1093/nar/5.4.1207PubMedPubMedCentralCrossRef Skehel JJ, Hay AJ: Nucleotide sequences at the 5’ termini of influenza virus RNAs and their transcripts. Nucleic Acids Res 1978, 5: 1207-1219. 10.1093/nar/5.4.1207PubMedPubMedCentralCrossRef
29.
go back to reference Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y: "Ambisense" approach for the generation of influenza a virus: vRNA and mRNA synthesis from one template. Virology 2000, 267: 310-317. 10.1006/viro.1999.0140PubMedCrossRef Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y: "Ambisense" approach for the generation of influenza a virus: vRNA and mRNA synthesis from one template. Virology 2000, 267: 310-317. 10.1006/viro.1999.0140PubMedCrossRef
30.
go back to reference Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97: 6108-6113. 10.1073/pnas.100133697PubMedPubMedCentralCrossRef Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97: 6108-6113. 10.1073/pnas.100133697PubMedPubMedCentralCrossRef
31.
go back to reference Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H: PB2 Protein of a highly pathogenic avian influenza virus strain a/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 2009, 83: 1572-1578. 10.1128/JVI.01879-08PubMedPubMedCentralCrossRef Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H: PB2 Protein of a highly pathogenic avian influenza virus strain a/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 2009, 83: 1572-1578. 10.1128/JVI.01879-08PubMedPubMedCentralCrossRef
32.
go back to reference Tsuda Y, Isoda N, Sakoda Y, Kida H: Factors responsible for plaque formation of a/duck/Siberia/272/1998 (H13N6) influenza virus on MDCK cells. Virus Res 2009, 140: 194-198. 10.1016/j.virusres.2008.12.005PubMedCrossRef Tsuda Y, Isoda N, Sakoda Y, Kida H: Factors responsible for plaque formation of a/duck/Siberia/272/1998 (H13N6) influenza virus on MDCK cells. Virus Res 2009, 140: 194-198. 10.1016/j.virusres.2008.12.005PubMedCrossRef
33.
go back to reference Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, Stuart AC, Marti-Renom MA, Madhusudhan MS, Yerkovich B, Sali A: Tools for comparative protein structure modeling and analysis. Nucleic Acids Res 2003, 31: 3375-3380. 10.1093/nar/gkg543PubMedPubMedCentralCrossRef Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, Stuart AC, Marti-Renom MA, Madhusudhan MS, Yerkovich B, Sali A: Tools for comparative protein structure modeling and analysis. Nucleic Acids Res 2003, 31: 3375-3380. 10.1093/nar/gkg543PubMedPubMedCentralCrossRef
34.
35.
go back to reference Laskowsk RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993, 26: 283-291. 10.1107/S0021889892009944CrossRef Laskowsk RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993, 26: 283-291. 10.1107/S0021889892009944CrossRef
36.
go back to reference Eisenberg D, Lüthy R, Bowie JU: VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997, 277: 396-404.PubMedCrossRef Eisenberg D, Lüthy R, Bowie JU: VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997, 277: 396-404.PubMedCrossRef
37.
go back to reference Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49: 3315-3321. 10.1021/jm051197ePubMedCrossRef Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49: 3315-3321. 10.1021/jm051197ePubMedCrossRef
Metadata
Title
Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes
Authors
Yurie Motohashi
Manabu Igarashi
Masatoshi Okamatsu
Takeshi Noshi
Yoshihiro Sakoda
Naoki Yamamoto
Kimihito Ito
Ryu Yoshida
Hiroshi Kida
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-118

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.